Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma

New Jersey-Based Slayback Founded A Decade Ago; Received KKR, Everstone Investments

In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.

Mergers & Acquisitions - Image
• Source: Shutterstock

Azurity Pharmaceuticals, a Massachusetts-based firm focused on the 505(b)(2) hybrid new drug application pathway, says it looks forward to bringing its commercial expertise to Slayback Pharma’s pipeline after acquiring the New Jersey-based 505(b)(2) and complex generics firm for an undisclosed fee.

Announcing its completion of a deal for Slayback from existing investors including KKR and Everstone Capital, Azurity said the acquisition “brings together companies with complementary strengths, enhancing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business